Research Paper Volume 14, Issue 9 pp 4158—4175
CCL19 has potential to be a potential prognostic biomarker and a modulator of tumor immune microenvironment (TIME) of breast cancer: a comprehensive analysis based on TCGA database
Figure 2. The association of Immune/Stromal/ESTIMATE score and the survival or clinic-pathological characteristics of breast cancer patients. (A–C) Kaplan–Meier survival analysis was applied to evaluate the associations between Immune/Stromal/ESTIMATE Score and the survival of breast cancer patients. Patients were divided into two groups, high score group and low score group, compared with the median. P-value and the number of samples in each group were displayed in the diagram; (D–H) The associations of Stromal Score with age, stage and TNM classification of breast cancer patients; (I–M) The associations of Immune Score with age, stage and TNM classification of breast cancer patients; (N–R) The associations of ESTIMATE Score with age, stage and TNM classification of breast cancer patients.